In this issue:
Response-adapted lenalidomide maintenance in new MM
Daratumumab for intermediate- or high-risk smouldering MM
Autologous SCT vs. VMP, ±VRD consolidation and lenalidomide maintenance in new MM
Genomic profiling for identifying risk of progression from smouldering MM
Disease recurrence risk and survival in MM
Carfilzomib + dexamethasone ±daratumumab for relapsed/refractory MM
Prolonged lenalidomide maintenance improves MM response depth
Serum parameters for identifying risk of smouldering MM progression
Morbidity burden in MM survivors after autologous BMT
Lenalidomide-based induction and maintenance in elderly new MM
Please login below to download this issue (PDF)